Madison Elsaadi
Stock Analyst at B. Riley Securities
(4.67)
# 910
Out of 4,600 analysts
59
Total ratings
58.7%
Success rate
40.3%
Average return
Main Sectors:
Stocks Rated by Madison Elsaadi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals | Reiterated: Buy | $123 | $87.85 | +40.01% | 7 | Aug 5, 2026 | |
| CAPR Capricor Therapeutics | Rated: Buy | $63 | $4.13 | +1,425.42% | 7 | Jul 31, 2026 | |
| WVE Wave Life Sciences | Reiterated: Buy | $31 → $22 | $5.99 | +267.28% | 15 | Jul 31, 2026 | |
| VNDA Vanda Pharmaceuticals | Maintained: Buy | $17 | $5.31 | +220.15% | 5 | Jul 22, 2026 | |
| SPRB Spruce Biosciences | Initiated Coverage: Buy | $160 | $45.93 | +248.36% | 1 | Jul 13, 2026 | |
| ETON Eton Pharmaceuticals | Reiterated: Buy | $40 | $46.96 | -14.82% | 14 | Jun 25, 2026 | |
| OVID Ovid Therapeutics | Reiterated: Buy | $5 | $2.60 | +92.31% | 4 | May 13, 2026 | |
| IRD Opus Genetics | Maintained: Buy | $9 → $10 | $3.74 | +167.38% | 2 | Apr 30, 2026 | |
| CMPS COMPASS Pathways | Initiated Coverage: Buy | $17 | $12.69 | +33.96% | 1 | Apr 24, 2026 | |
| FENC Fennec Pharmaceuticals | Initiated Coverage: Buy | $16 | $10.50 | +52.38% | 1 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $179 | $216.19 | -17.20% | 1 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $8.11 | n/a | 1 | Jan 23, 2025 |
Arrowhead Pharmaceuticals
Aug 5, 2026
Reiterated: Buy
Price Target: $123
Current: $87.85
Upside: +40.01%
Capricor Therapeutics
Jul 31, 2026
Rated: Buy
Price Target: $63
Current: $4.13
Upside: +1,425.42%
Wave Life Sciences
Jul 31, 2026
Reiterated: Buy
Price Target: $31 → $22
Current: $5.99
Upside: +267.28%
Vanda Pharmaceuticals
Jul 22, 2026
Maintained: Buy
Price Target: $17
Current: $5.31
Upside: +220.15%
Spruce Biosciences
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $160
Current: $45.93
Upside: +248.36%
Eton Pharmaceuticals
Jun 25, 2026
Reiterated: Buy
Price Target: $40
Current: $46.96
Upside: -14.82%
Ovid Therapeutics
May 13, 2026
Reiterated: Buy
Price Target: $5
Current: $2.60
Upside: +92.31%
Opus Genetics
Apr 30, 2026
Maintained: Buy
Price Target: $9 → $10
Current: $3.74
Upside: +167.38%
COMPASS Pathways
Apr 24, 2026
Initiated Coverage: Buy
Price Target: $17
Current: $12.69
Upside: +33.96%
Fennec Pharmaceuticals
Feb 12, 2026
Initiated Coverage: Buy
Price Target: $16
Current: $10.50
Upside: +52.38%
Oct 1, 2025
Initiated Coverage: Buy
Price Target: $179
Current: $216.19
Upside: -17.20%
Jan 23, 2025
Reiterated: Buy
Price Target: $11
Current: $8.11
Upside: n/a